NAD Recommends Arcadia Consumer Healthcare Discontinue Its “#1 Pharmacist Recommended” Claim

For Immediate Release 
Contact: Abby Hills, Director of Communications, BBB National Programs 

703.247.9330 / 

New York, NY – September 8, 2020 – The National Advertising Division of BBB National Programs found that Arcadia Consumer Healthcare did not provide sufficiently reliable evidence to support its “#1 Pharmacist Recommended” claim and recommended the claim, challenged by Advantice Health, be discontinued. The advertiser agreed to comply with NAD’s recommendation.  

Express Claim 

  • “#1 Pharmacist Recommended” 

Implied Claim 

  • Fungi-Nail antifungal products, which treat athlete’s foot, including the Fungi-Nail Anti-Fungal Pen, Fungi-Nail Anti-Fungal Liquid, and Fungi-Nail Anti-Fungal Ointment, are the #1 Pharmacist Recommended” brand/product for all fungal infections. 

As support for the challenged claims, the advertiser submitted a survey to assess “the awareness and recommendation level of 5 OTC products which treat fungus on the skin around the toenail.” The five products included in the pharmacist-directed survey were Fungi-Nail, FungiCure, ProClearz, Tineacide, and Mycocide. The survey asked “When recommending a brand or product that treats fungus on the skin around the toenail, what brands or products do you recommend? (select all that apply).” The results demonstrated that 73% of the surveyed pharmacists recommend Fungi-Nail. 

Although NAD determined that the survey had an appropriate survey population, was geographically diverse, and asked a question designed to assess what products the pharmacists actually recommend in their practice, the five products included in the survey were not representative of the entire OTC antifungal marketplace. Lamisil, Lotrimin, and Tinactin, the undisputed brand leaders, were not listed as options for the pharmacists to recommend in the survey.  

NAD was not persuaded by the advertiser’s contention that it is a specialty product and, therefore, belonged in a different product category than the leading antifungal brands obviating the need to compare Fungi-Nail to the brand leaders in the survey. Moreover, the survey was conducted on a prior product formulation instead of the current product formulation. Lastly, the survey was further flawed by its failure to ask open-ended questions and impermissibly conflated brand claims and product claims. NAD therefore recommended the advertiser discontinue the “#1 Pharmacist Recommended” claim. 

In its advertiser’s statement, the advertiser stated that it “appreciates NAD’s attention to this matter and agrees to comply.” 


About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit 

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.     

Latest News

Press Release

BBB National Programs National Advertising Division Launches Expedited Fast-Track SWIFT Lane Designed to Address Misleading Advertising Disclosures

New York, NY – November 9, 2021 – Mindful of recent Federal Trade Commission (FTC) actions, BBB National Programs today announced a new, streamlined lane of the expedited Fast-Track SWIFT challenge submission process, one designed specifically to address the prominence and sufficiency of...

Read the Release
Press Release

Media Advisory: FTC Commissioner Rebecca Slaughter to Keynote National Advertising Division “Future of Ad Law” 2021 Annual Conference

New York, NY – September 21, 2021 – In its 50th anniversary year, the National Advertising Division (NAD) of BBB National Programs will host the NAD 2021 Annual Conference virtually next week, running Wednesday, September 29 through Friday, October 1. Members of the media are invited to cover NAD 2021 with...

Read More
Press Release

Children’s Advertising Review Unit Issues Revised Guidelines for Responsible Advertising to Children, Effective January 1, 2022

McLean, VA – July 29, 2021 – BBB National Programs’ Children’s Advertising Review Unit (CARU) today announced the issuance of the revised CARU Advertising Guidelines, widely recognized industry standards to assure that advertising directed to children is not deceptive, unfair, or inappropriate for its intended...

Read the Press Release
Press Release

U.S.-Based BBB National Programs Announced as Winner for “Best Sectoral Initiative” by International Council of Advertising Self-Regulation

On 15 June 2021, the International Council for Advertising Self-Regulation (ICAS) announced the winners of its second edition of the ICAS Global Awards. The objective of the ICAS Awards is to reward initiatives that contribute to responsible marketing practices and a more effective and impactful...

Read the Press Release